TY - JOUR
T1 - ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function
AU - Murakami, Tetsuro
AU - Qamar, Seema
AU - Lin, Julie Qiaojin
AU - Schierle, Gabriele S.Kaminski
AU - Rees, Eric
AU - Miyashita, Akinori
AU - Costa, Ana R.
AU - Dodd, Roger B.
AU - Chan, Fiona T.S.
AU - Michel, Claire H.
AU - Kronenberg-Versteeg, Deborah
AU - Li, Yi
AU - Yang, Seung Pil
AU - Wakutani, Yosuke
AU - Meadows, William
AU - Ferry, Rodylyn Rose
AU - Dong, Liang
AU - Tartaglia, Gian Gaetano
AU - Favrin, Giorgio
AU - Lin, Wen Lang
AU - Dickson, Dennis W.
AU - Zhen, Mei
AU - Ron, David
AU - Schmitt-Ulms, Gerold
AU - Fraser, Paul E.
AU - Shneider, Neil A.
AU - Holt, Christine
AU - Vendruscolo, Michele
AU - Kaminski, Clemens F.
AU - St George-Hyslop, Peter
N1 - Funding Information:
Supported by Canadian Institutes of Health Research (P.E.F. and P.S.G.-H.), Alzheimer Society of Ontario (P.E.F., P.St.G.H.), Wellcome Trust (P.S.G.-H., M.V., C.F.K., G.S.K.S., D.R., and C.H.), Medical Research Council (P.S.G.-H., M.V., C.F.K., and G.S.K.S.), NIH Research, Alzheimer Research UK (C.F.K. and G.S.K.S.), Gates Cambridge Scholarship (J.Q.L.), Engineering and Physical Sciences Research Council (C.F.K. and G.S.K.S.), European Research Council Starting Grant RIBOMYLOME_309545 (G.G.T.), European Research Council under the European Union’s Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 322817 (C.H.), and National Institute of Neurological Disorders and Stroke R01 NS07377 (N.A.S.). The authors thank Tom Cech and Roy Parker for helpful discussions.
Funding Information:
Supported by Canadian Institutes of Health Research (P.E.F. and P.S.G.-H.), Alzheimer Society of Ontario (P.E.F., P.St.G.H.), Wellcome Trust (P.S.G.-H., M.V., C.F.K., G.S.K.S., D.R., and C.H.), Medical Research Council (P.S.G.-H., M.V., C.F.K., and G.S.K.S.), NIH Research, Alzheimer Research UK (C.F.K. and G.S.K.S.), Gates Cambridge Scholarship (J.Q.L.), Engineering and Physical Sciences Research Council (C.F.K. and G.S.K.S.), European Research Council Starting Grant RIBOMYLOME_309545 (G.G.T.), European Research Council under the European Union’s Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 322817 (C.H.), and National Institute of Neurological Disorders and Stroke R01 NS07377 (N.A.S.). The authors thank Tom Cech and Roy Parker for helpful discussions.
Publisher Copyright:
© 2015 The Authors.
PY - 2015/11/18
Y1 - 2015/11/18
N2 - The mechanisms by which mutations in FUS and other RNA binding proteins cause ALS and FTD remain controversial. We propose a model in which low-complexity (LC) domains of FUS drive its physiologically reversible assembly into membrane-free, liquid droplet and hydrogel-like structures. ALS/FTD mutations in LC or non-LC domains induce further phase transition into poorly soluble fibrillar hydrogels distinct from conventional amyloids. These assemblies are necessary and sufficient for neurotoxicity in a C. elegans model of FUS-dependent neurodegeneration. They trap other ribonucleoprotein (RNP) granule components and disrupt RNP granule function. One consequence is impairment of new protein synthesis by cytoplasmic RNP granules in axon terminals, where RNP granules regulate local RNA metabolism and translation. Nuclear FUS granules may be similarly affected. Inhibiting formation of these fibrillar hydrogel assemblies mitigates neurotoxicity and suggests a potential therapeutic strategy that may also be applicable to ALS/FTD associated with mutations in other RNA binding proteins.
AB - The mechanisms by which mutations in FUS and other RNA binding proteins cause ALS and FTD remain controversial. We propose a model in which low-complexity (LC) domains of FUS drive its physiologically reversible assembly into membrane-free, liquid droplet and hydrogel-like structures. ALS/FTD mutations in LC or non-LC domains induce further phase transition into poorly soluble fibrillar hydrogels distinct from conventional amyloids. These assemblies are necessary and sufficient for neurotoxicity in a C. elegans model of FUS-dependent neurodegeneration. They trap other ribonucleoprotein (RNP) granule components and disrupt RNP granule function. One consequence is impairment of new protein synthesis by cytoplasmic RNP granules in axon terminals, where RNP granules regulate local RNA metabolism and translation. Nuclear FUS granules may be similarly affected. Inhibiting formation of these fibrillar hydrogel assemblies mitigates neurotoxicity and suggests a potential therapeutic strategy that may also be applicable to ALS/FTD associated with mutations in other RNA binding proteins.
UR - http://www.scopus.com/inward/record.url?scp=84960129723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960129723&partnerID=8YFLogxK
U2 - 10.1016/j.neuron.2015.10.030
DO - 10.1016/j.neuron.2015.10.030
M3 - Article
C2 - 26526393
AN - SCOPUS:84960129723
SN - 0896-6273
VL - 88
SP - 678
EP - 690
JO - Neuron
JF - Neuron
IS - 4
ER -